GynecologyGynecology2079-56962079-5831Consilium Medicum3497510.26442/20795696.2020.3.200210Research ArticleSystematic analysis of the biological roles and pharmacological properties of D-chiro-inositolGromovaOlga A.<p>D. Sci. (Med.), Prof</p>unesco.gromova@gmail.comhttps://orcid.org/0000-0002-7663-710XTorshinIvan Yu.<p>Cand. Sci. (Phys.-Math.), Cand. Sci. (Chem.)</p>unesco.gromova@gmail.comhttps://orcid.org/0000-0002-2659-7998UvarovaElena V.<p>D. Sci. (Med.), Prof</p>unesco.gromova@gmail.comTapilskayaNatalya I.<p>D. Sci. (Med.), Prof.</p>unesco.gromova@gmail.comhttps://orcid.org/0000-0001-5309-0087KalachevaAlla G.<p>Cand. Sci. (Med.)</p>alla_kalacheva@mail.ruhttps://orcid.org/0000-0001-6144-5781Federal Research Center «Computer Science and Management»Lomonosov Moscow State UniversityKulakov National Medical Research Center for Obstetrics, Gynecology and PerinatologySechenov First Moscow State Medical University (Sechenov University)Ott Research Institute of Obstetrics, Gynecology and ReproductologySaint Petersburg State Paediatric Medical UniversityIvanovo State Medical Academy09072020223212808072020Copyright © 2020, Consilium Medicum2020<p style="text-align: justify;">D-chiroinositol (DCI) is one of the 9 inositol isomers that forms inositol phosphoglycans, which are mediators of the action of insulin. The metabolism of DCI and myo-inositol (MI) is impaired against the background of insulin resistance, including the patients with polycystic ovary syndrome (PCOS).</p>
<p style="text-align: justify;"><strong>Aim. </strong>Highlight the most characteristic pharmacological properties of DCI.</p>
<p style="text-align: justify;"><strong>Materials and methods. </strong>Systematic computer analysis of 45 600 publications on the biological roles of inositol by methods of the topological theory of pattern recognition and systems biology analysis of human proteome.</p>
<p style="text-align: justify;"><strong>Results. </strong>A complex of interactions between metabolic disorders of DCI, PCOS, ovulation disorders, obesity associated with numerous hormonal disorders is described. Supplements with DCI and MI increase the sensitivity of cells to insulin and normalize the metabolism of androgens. An important difference between DCI and MI is the presence of DCI in the composition of inositol phosphoglycans that mediate the action of insulin on cells, as well as its participation in the realization of the therapeutic effects of metformin. The use of the MI+DCI combination allows achieving positive dynamics in reducing excess body weight, normalizing blood lipids, glucose and insulin levels, restoring the ovulatory menstrual cycle, improving oocyte quality, and helps prevent gestational diabetes in pregnant women and macrosomia of the fetus. DCI is more effective than MI in reducing the risk of folate-resistant neural tube defects.</p>
<p style="text-align: justify;"><strong>Conclusion. </strong>The therapeutic potential of DCI in combination with MI for treating PCOS and hyperandrogenism is evident. Depending on the therapeutic expediency, various ratios of MI:DCI can be used for the treatment of PCOS and disorders of carbohydrate and lipid metabolism.A</p>restoration of insulin sensitivityinositolovulationhyperandrogenismandrogen metabolismDikirogenвосстановление чувствительности к инсулинуинозитолыовуляциягиперандрогенияметаболизм андрогеновДикироген[Unfer V, Nestler JE, Kamenov ZA et al. Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials. Int J Endocrinol 2016; 2016: 1849162. DOI: 10.1155/2016/1849162][Громова О.А., Торшин И.Ю., Гришина Т.Р. и др. Систематический анализ молекулярно-физиологических эффектов миоинозитола: данные молекулярной биологии, экспериментальной и клинической медицины. Эффективная фармакотерапия. 2013; 28: 32–41.][[Gromova O.A., Torshin I.Yu., Grishina T.R. et al. Systematic analysis of the molecular physiological effects of myoinositol: data from molecular biology, experimental and clinical medicine. Effective pharmacotherapy. 2013; 28: 32–41 (in Russian).]][Громова О.А., Торшин И.Ю., Калачева А.Г., Тетруашвили Н.К. Роли мио-инозитола в поддержании репродуктивного здоровья женщины. Повышение эффективности технологий экстракорпорального оплодотворения. РМЖ. Мать и дитя. 2018; 1 (1): 88–95. DOI: 10.32364/2618-8430-2018-1-1-88-95][[Gromova O.A., Torshin I.Yu., Kalacheva A.G. et al. The role of myo-inositol in maintaining the reproductive health of women. Improving the effectiveness of in vitro fertilization technologies. Breast cancer. Mother and Child 2018; 1 (1): 88–95. DOI: 10.32364/2618-8430-2018-1-1-88-95 (in Russian).]][Thomas MP, Mills SJ, Potter BV. The «Other» Inositols and Their Phosphates: Synthesis, Biology, and Medicine (with Recent Advances in myo-Inositol Chemistry). Angew Chem Int Ed Engl 2016; 55 (5): 1614–50. DOI: 10.1002/anie.201502227][Vitagliano A, Saccone G, Cosmi E et al. Inositol for the prevention of gestational diabetes: a systematic review and meta-analysis of randomized controlled trials. Arch Gynecol Obstet 2019; 299 (1): 55–68. DOI: 10.1007/s00404-018-5005-0][Giménez-Bastida JA, Zieliński H. Buckwheat as a Functional Food and Its Effects on Health. J Agric Food Chem 2015; 63 (36): 7896–913. DOI: 10.1021/acs.jafc.5b02498][Torshin I.Yu., Rudakov K.V. On metric spaces arising during formalization of recognition and classification problems. Part 1: properties of compactness. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications). 2016; 26 (2): 274.][Torshin I.Yu., Rudakov K.V. On metric spaces arising during formalization of problems of recognition and classification. Part 2: density properties. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications). 2016; 26 (3): 483–96.][Torshin I.Yu. Optimal Dictionaries output information based on the criterion of Solvability and their applications in Bioinformatics. Pattern Recognition and Image Analysis 2013; 23 (2): 319–27.][Torshin I.Yu., Rudakov K.V. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Part 2: metric approach within the framework of the theory of classification of feature values. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications). 2017; 27 (2): 184–99.][Jeon Y, Aja S, Ronnett GV, Kim EK. D-chiro-inositol glycan reduces food intake by regulating hypothalamic neuropeptide expression via AKT-FoxO1 pathway. Biochem Biophys Res Commun 2016; 470 (4): 818–23. DOI: 10.1016/j.bbrc.2016.01.115][Hada B, Yoo MR, Seong KM et al. D-chiro-inositol and pinitol extend the life span of Drosophila melanogaster. J Gerontol A Biol Sci Med Sci 2013; 68 (3): 226–34. DOI: 10.1093/gerona/gls156][Laganà AS, Unfer V. D-Chiro-Inositol’s action as aromatase inhibitor: rationale and potential clinical targets. Eur Rev Med Pharmacol Sci 2019; 23 (24): 10575–6. DOI: 10.26355/eurrev_201912_19752][Larner J. D-chiro-inositol in insulin action and insulin resistance-old-fashioned biochemistry still at work. IUBMB Life 2001; 51 (3): 139–48. DOI: 10.1080/152165401753544205][Rendle PM, Kassibawi F, Johnston KA et al. Synthesis and biological activities of d-chiro-inositol analogues with insulin-like actions. Eur J Med Chem 2016; 122: 442–51. DOI: 10.1016/j.ejmech.2016.06.047][Larner J. D-chiro-inositol – its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res 2002; 3 (1): 47–60. DOI: 10.1080/15604280212528][Baillargeon JP, Iuorno MJ, Apridonidze T, Nestler JE. Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome. Metab Syndr Relat Dis 2010; 8 (2): 127–36. DOI: 10.1089/met.2009.0052][Ostlund RE Jr, Seemayer R, Gupta S et al. A stereospecific myo-inositol/D-chiro-inositol transporter in HepG2 liver cells. Identification with D-chiro-[3-3H]inositol. J Biol Chem 1996; 271 (17): 10073–8. DOI: 10.1074/jbc.271.17.10073][Lazarenko R, Geisler J, Bayliss D et al. D-chiro-inositol glycan stimulates insulin secretion in pancreatic b cells. Mol Cell Endocrinol 2014; 387 (1–2): 1–7. DOI: 10.1016/j.mce.2014.02.004][Hu Y, Zhao Y, Ren D et al. Hypoglycemic and hepatoprotective effects of D-chiro-inositol-enriched tartary buckwheat extract in high fructose-fed mice. Food Funct 2015; 6 (12): 3760–9. DOI: 10.1039/c5fo00612k][Fan C, Liang W, Wei M et al. Effects of D-Chiro-Inositol on Glucose Metabolism in db/db Mice and the Associated Underlying Mechanisms. Front Pharmacol 2020; 11: 354. DOI: 10.3389/fphar.2020.00354][Ostlund RE Jr, McGill JB, Herskowitz I et al. D-chiro-inositol metabolism in diabetes mellitus. Proc Natl Acad Sci USA 1993; 90 (21): 9988–92. DOI: 10.1073/pnas.90.21.9988][Murphy A, Shamshirsaz A, Markovic D et al. Urinary Excretion of Myo-Inositol and D-Chiro-Inositol in Early Pregnancy Is Enhanced in Gravidas With Gestational Diabetes Mellitus. Reprod Sci 2016; 23 (3): 365–71. DOI: 10.1177/1933719115602767][La Marca A, Grisendi V, Dondi G et al. The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective study. Gynecol Endocrinol 2015; 31 (1): 52–6. DOI: 10.3109/09513590.2014.964201][Iuorno MJ, Jakubowicz DJ, Baillargeon JP et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 2002; 8 (6): 417–23. DOI: 10.4158/EP.8.6.417][Nestler JE, Jakubowicz DJ, Reamer P et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999; 340 (17): 1314–20. DOI: 10.1056/NEJM199904293401703][Baillargeon JP, Iuorno MJ, Jakubowicz DJ et al. Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89 (1): 242–9. DOI: 10.1210/jc.2003-030437][Galazis N, Galazi M, Atiomo W. D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review. Gynecol Endocrinol 2011; 27 (4): 256–62. DOI: 10.3109/09513590.2010.538099][Fonteles MC, Almeida MQ, Larner J. Antihyperglycemic effects of 3-O-methyl-D-chiro-inositol and D-chiro-inositol associated with manganese in streptozotocin diabetic rats. Horm Metab Res 2000; 32 (4): 129–32. DOI: 10.1055/s-2007-978606][Gluck G, Anguelova T, Heimark D, Larner J. Synergistic Effects of d-Chiro-Inositol and Manganese on Blood Glucose and Body Weight of Streptozotocin-Induced Diabetic Rats. Curr Bioactive Compounds 2010; 6: 90. DOI: 10.2174/157340710791184831][Dell’Edera D, Sarlo F, Allegretti A et al. The influence of D-chiro-inositol and D-myo-inositol in pregnant women with glucose intolerance. Biomed Rep 2017; 7 (2): 169–72. DOI: 10.3892/br.2017.939][Maurizi AR, Menduni M, Del Toro R et al. A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes. Acta Diabetol 2017; 54 (4): 361–5. DOI: 10.1007/s00592-016-0954-x][Malvasi A, Casciaro F, Minervini MM et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. Eur Rev Med Pharmacol Sci 2014; 18 (2): 270–4. PMID: 24488919.][Cheng F, Han L, Xiao Y et al. D-chiro-Inositol Ameliorates High Fat Diet-Induced Hepatic Steatosis and Insulin Resistance via PKCe-PI3K/AKT Pathway. J Agric Food Chem 2019; 67 (21): 5957–67. DOI: 10.1021/acs.jafc.9b01253][Zhao SS, Li NR, Zhao WL et al. D-chiro-inositol effectively attenuates cholestasis in bile duct ligated rats by improving bile acid secretion and attenuating oxidative stress. Acta Pharmacol Sin 2018; 39 (2): 213–21. DOI: 10.1038/aps.2017.98][Carlomagno G, Unfer V, Roseff S. The D-chiro-inositol paradox in the ovary. Fertil Steril 2011; 95 (8): 2515–6. DOI: 10.1016/j.fertnstert.2011.05.027][Laganà AS, Garzon S, Casarin J et al. Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach. Trends Endocrinol Metab 2018; 29 (11): 768–80. DOI: 10.1016/j.tem.2018.09.001][Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE Jr et al. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 2006; 29 (2): 300–5. DOI: 10.2337/diacare.29.02.06.dc05-1070][Ravanos K, Monastra G, Pavlidou T et al. Can high levels of D-chiro-inositol in follicular fluid exert detrimental effects on blastocyst quality? Eur Rev Med Pharmacol Sci 2017; 21 (23): 5491–8. DOI: 10.26355/eurrev_201712_13940][Cogram P, Tesh S, Tesh J et al. D-chiro-inositol is more effective than myo-inositol in preventing folate-resistant mouse neural tube defects. Hum Reprod 2002; 17 (9): 2451–8. DOI: 10.1093/humrep/17.9.2451][Nordio M, Basciani S, Camajani E. The 40: 1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur Rev Med Pharmacol Sci 2019; 23 (12): 5512–21. DOI: 10.26355/eurrev_201906_18223][Le Donne M, Metro D, Alibrandi A et al. Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci 2019; 23 (5): 2293–301. DOI: 10.26355/eurrev_201903_17278][Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci 2012; 16 (5): 575–81. PMID: 22774396.][Januszewski M, Issat T, Jakimiuk AA et al. Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS). Ginekol Pol 2019; 90 (1): 7–10. DOI: 10.5603/GP.2019.0002][Mendoza N, Diaz-Ropero MP, Aragon M et al. Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol Endocrinol 2019; 35 (8): 695–700. DOI: 10.1080/09513590.2019.1576620][Mendoza N, Galan MI, Molina C et al. High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol Endocrinol 2020; 36 (5): 398–401. DOI: 10.1080/09513590.2019.1681959][Pizzo A, Laganà AS, Barbaro L. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecol Endocrinol 2014; 30 (3): 205–8. DOI: 10.3109/09513590.2013.860120][Громова О.А., Торшин И.Ю., Андреева Е.Н. и др. Системно-биологический анализ ролей марганца в акушерстве и гинекологии: репродуктивное здоровье женщины, регуляция менструального цикла и профилактика пороков развития плода. Вопр. гинекологии, акушерства и перинатологии. 2020; 19 (1): 103–13. DOI: 10.20953/1726-1678-2020-1-103-113][[Gromova O.A., Torshin I.Yu., Andreeva E.N. et al. System-biological analysis of the roles of manganese in obstetrics and gynecology: reproductive health of women, regulation of the menstrual cycle and prevention of fetal malformations. Questions of Gynecology, Obstetrics and Perinatology. 2020; 19 (1): 103–13. DOI: 10.20953/1726-1678-2020-1-103-113 (in Russian).]]